Abstract
Ocular drug delivery is the most fascinating and challenging task faced by pharmaceutical researchers. Conventional dosage forms such as eye drops are the most used dosage form by ocular route, in spite of their low bioavailability and the pulsed release of the drug where it is expected that direct application of the drug to the eye will give maximum response; however after instillation of an eye drop, about 70% of the administered volume can be seen to be lost by different factors. For this reason new ocular drug delivery vehicles have been developed in order to minimize the amount of the drug lost from the eye and at the same time provide maximum response with reduced frequency of administration. Transport of drugs applied by traditional dosage forms is restricted to the eye, and therapeutic drug concentrations in the target tissues are not maintained for a long duration since the eyes are protected by a unique anatomy and physiology. Major problems encountered by conventional ocular dosage forms include rapid pre-corneal drug loss due to naso-lacrimal drainage; tear turnover and drug dilution resulting in poor bio-availability. Therefore, efforts to improve ocular drug bio-availability led to development of novel drug delivery dosage forms such as nano particles, liposomes, hydrogels, ocuserts and muco-adhesive formulations.
References
Sikandar et al., Ocular drug delivery system: an overview. Int. J. Phar. Sci. Res, 2(5): 1168-1175,(2011)
Reeta Rani Thakur et al., Modern Delivery Systems for Ocular Drug Formulations: A Comparative Overview
W.R.T Conventional Dosage Form. Int. J. Res. In. Phar & Biomed Sci, 2 (1): 8-18,(2011)
S.A.Menqi and S.G.Desh Pande (Eds.), In: N.K.Jain, Controlled and Novel drug delivery systems, CBS publishers, New Delhi, 2004, pp.82-96.
D.M.Brahmankar, Sunil B.Jaiswal, (Eds.), Biopharmaceutics and Pharmacokinetics a treatise, Valllabh Prakashan, 2010, pp.470-475.
Jeffery D.Henderer and Christopher J.Rapuano, In: Laurence L.Bruton Johns.La. Kerth L.parker (eds.), Goodman and Gilman`s the pharmacological basis of Therapeutics, McGarw-Hill, Newyork, 2006, pp.1707- 1735.
Yie W.Chien, Ed.Novel drug delivery systems, Vol-50, Informa health care, USA, 2011, pp. 269-275.
Lee, V.H.L, Ophthalmic drug delivery systems, Marcel Dekker, Newyork, 1993, pp.59-82.
Masood Chowhan, Alan L.Weiner, and Harsh Bhagat (Eds.), In: James Swabrick, Encyclopedia of Pharamaceutical technology, Informa healthcare, USA, 2007, pp.1220-1225.
Clive G.Wilson,Y.P.Zhu,P.Kurmala,L.S.Rao and B.Dhillon. Ophthalmic drug Delivery. In: Anya M.Hillery, Andrew W.Lloyd James Swabrick (eds.),Drug Delivery and targeting, Taylor and Francis e-library, London,2005,pp.298-318.
D.M.Brahmankar, Sunil B.Jaiswal, (Eds.), Biopharmaceutics and Phamracokinetics a treatise, Valllabh Prakashan, 2010, pp.470-475.
S.P.Vyas, R.K.Khar, Ed.Targeted and controlled drug delivery, CBS Publishers, New Delhi, 2011, pp.374-375.
O.Felt, V.Baeyens, M.Zignani, P.Buri, R.Gurny (Eds.), In: Edith Mathiowitz, Encyclopedia of Controlled Drug Delivery, Wiley-Interscience, Newyork, 1999, pp.605- 616.
Ravi s. Talluri, Gyan prakash mishra, and Ashim k.RobertO.williamШ David R.Taft Jason T. McConvile (eds.), Advanced drug formulation design to optimize therapeutic outcomes, Informa health care, USA, 2008, pp.143-170.
David jones, Fast track pharmaceutics-Dosage form & Design, Pharmaceutical press, London, 2008, pp.135- 136.
S.P.Vyas, R.K.Khar, Ed.Targeted and controlled drug delivery, CBS Publishers, New Delhi, 2011, pp.123-125.
PatrickJ.Sinko, Martins physical pharmacy and pharmaceutical sciences, 5th Edition, Lippincott Williams, 2006, pp. 645-649.
Kishan Singh et al., Novel Approaches in Formulation and Drug Delivery using Contact Lenses. J. Bas. Clin. Phar, 2(2): 87-101, (2011)
Horward C.sAnsel loyd Y.Allen,jr.Nicholas G.Popovich,(Eds.),Ansels Pharmaceutical dosage forms and drug delivery systems,8th edition.Lippincott Williams,2005,pp.662-663.
A.rajasekaran et al., A comparative review on conventional and advanced ocular drug delivery formulations. Int. J. Phar. Tech. Res, 2(1): 668-674(2010)
Agrawal Y K et al., Current status and advanced approaches in ocular drug delivery system. J. Glob. Tren. In .Phar. Sci, 2(2): 131-148, (2011)
D.M.Brahmankar, Sunil B.Jaiswal, (Eds.), Biopharmaceutics and Phamracokinetics a treatise, Valllabh Prakashan, 2010, pp.470-475.
Singh V. et al., The challenges of ophthalmic drug delivery: a review, Int. J. Drug. Disc, 3(1): 56-62, (2011)
Robinson, J.C, Ophthalmic drug delivery systems, Marcel Dekker, Newyork, 1993, pp.27-58.
Rootman DS, Jantzen JA, Gonzalez JR, Fischer MJ, Beuerman R, Hill JM,Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit, Invest Ophthalmol Vis Sci, 29, 1988, 1397-1401.
Callegan MC, Hobden JA, O’Callaghan RJ, Hill JM, Ocular drug delivery: A comparison of transcorneal iontophoresis to corneal collagen shields, Int J Pharma, 123, 1995, 173-179.
Kaur IP, Kanwar M, Ocular preparations: The formulation approach, drug development and industrial pharmacy, 28(5), 2002, 473-493.
Vasantha R, Sehgal PK, Rao P, Collagen ophthalmic inserts for Pilocarpine drug delivery system, Int J Pharma, 47, 1988, 95-102.
Vandamme TF, Micro emulsions as ocular drug delivery systems: recent developments and future challenges, Prog. Retin. Eye Res, 21, 2002, 15–34.
Vasantha R, Sehgal PK, Rao P. Collagen ophthalmic inserts for Pilocarpine drug delivery system. Int J Pharma 1988; 47:95-102.
Kaufman HE, Steinemann TL, Lehman E, Thompson HW, Varnell ED, Jacob-Labarre T, et al. J Ocul Pharma 1994;10:17-27.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array